Cardiology

Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.

The congress president shares her favorite sessions, and ideas to integrate virtual setting successes into next year's meeting.

The largest and most comprehensive look at blood pressure therapies and cardiovascular disease risk to date is providing an overview of the effects of antihypertensive therapy at varying levels of baseline blood pressure.

Results of HOME-PE suggest an approach using HESTIA was noninferior to sPESI for patients with acute pulmonary embolism.

New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.

According to late breaking data, younger women exhibit a decreased risk for heart attack mortality due to estrogen’s protective effect

Analysis of the UK Biobank cohort details associations between increased HbA1c levels and risk of myocardial infarction in patients regardless of sex.

What ESC has learned about the benefits and difficulties of online-only forums.

Evolocumab and alirocumab produced LDL-C reduction in patients regardless of underlying mutations, investigators reported.

This underscores a need to reinvent cities and address environmental risk factors that are associated with increased risk for cardiovascular diseases.

Myocardial infarction patients were provided ECG readings as reliable as those provided by standard devices.

Studies have shown that heat-related cardiovascular events have increased over recent years.

New cohort data shows that at least 40% of COVID-19 positive patients had CV risk factors, such as diabetes and hypertension.

Dapagliflozin and empagliflozin are shown to minimize CV events in patients with heart failure and a reduced ejection fraction.

A look at how a major international cardiovascular meeting changed its structure in 4 months.

A look at how different organisms are influenced differently by harmful foods or common therapies linked to cardiovascular risks.

Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.

New findings suggest the "obesity paradox" may be explained by rates of exercise among women.

Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.

The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.

The new findings break ground on placebo-controlled assessment of the PCSK9 inhibitor for the pediatric population.

Full data from the EVAPORATE trial presented at ESC Congress 2020 add further evidence of the cardiovascular benefits from use of icosapent ethyl.

A look at how asymptomatic AFib is being combatted by consumer devices and embraced, large-scale population research.

New cohort analyses show very few patients with atrial fibrillation exercise regularly or rigorously—which could be a detriment to their mortality risk.

Daniel Gaudet, MD, PhD, discusses what's next in clinical pursuits of the greatly underdiagnosed hereditary cardiovascular disease.